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Abstract We have demonstrated over a decade ago that
hepoxilins cause the release of insulin from isolated pancreatic
islets of Langerhans in vitro. However, no studies are available so
far to indicate whether these compounds are active in vivo. The
present study is the first to our knowledge which demonstrates
that hepoxilins administered intra-arterially in the anaesthetized
rat cause the release of insulin in the circulation. This release is
dependent on the glucose status of the rat. Hence, animals fasted
overnight do not respond to hepoxilin administration, while
animals that have had free access to food respond to hepoxilins
with a rise in insulin concentrations in blood. The hepoxilin effect
is rapid and varies with different hepoxilins, the most potent of
which is hepoxilin A3 (HxA3) (both the 8S and the 8R
enantiomers). Administration of 100 Wg HxA3 produces a rise
in blood insulin equivalent to that caused by the administration of
5 mg glucose. In view of earlier evidence showing that these
compounds cause a rise in intracellular calcium levels in vitro at
a 6 1 Wg/ml concentration through a receptor-mediated mechan-
ism, we speculate that the actions of hepoxilins in causing the
release of insulin from the pancreas may be due to alterations in
calcium levels within the L-cell. We believe that hepoxilins may
represent new lead compounds as therapeutics in type II diabetes
mellitus.
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1. Introduction
Hepoxilins were discovered in the early 1980s [1,2]. They
are lipidic compounds derived from arachidonic acid via the
12-lipoxygenase pathway [3,4]. Hence, 12(S)-HPETE, the ini-
tial product of 12(S)-lipoxygenase, is enzymatically trans-
formed into two hydroxy-epoxide products named hepoxilin
A3 (HxA3) and hepoxilin B3 (HxB3) [5]. The in vivo formation
of HxA3 after administration of arachidonic acid in the rat
has been reported [2]. These compounds are biologically un-
stable through enzymatic pathways known to catabolize them
[6]. Early studies in the rat showed that HxA3 was capable of
e¡ecting the release of insulin from isolated perifused islets of
Langerhans in vitro [7]. Additional studies using single cells
showed that HxA3 caused a rise in intracellular calcium that
was independent of extracellular calcium, indicating that he-
poxilin caused the release of calcium from intracellular calci-
um stores [8]. Calcium release is mediated by a hepoxilin-
speci¢c receptor present in the cell [9^11]. The purpose of this
study was to investigate whether the native hepoxilins (A and
B type) cause the release of insulin in vivo. No such studies
have been reported.
2. Materials and methods
2.1. Materials
HxA3 (8R and 8S epimers) and HxB3 (10R and 10S epimers) were
chemically synthesized as described previously [12]. Male Wistar rats
(200^220 g, body weight) were purchased from Charles River (St.
Constant, Que., Canada). They were maintained either without food
overnight or with regular food chow ad lib, with unlimited access to
water. On the day of the experiment, the animals were anaesthetized
with inactin (100 mg/kg, intraperitoneal; BYK-Gulden, Constanz,
Germany). The trachea and left carotid artery were cannulated for
respiration and blood sampling, respectively. Body temperature was
maintained at 37‡C by placing animals on a thermostatically con-
trolled heating box. The animals were lightly heparinized to prevent
blood coagulation during the experiment.
2.2. Experimental protocol
Two hours were allowed after the completion of surgery for the
animals to stabilize. Blood samples were withdrawn (300 Wl) at the
following time points: 310 min, 35 min and 30 s, 2, 5, 10, 30, 60 and
120 min after administration of the test compound. Fluid replacement
equivalent to the blood withdrawn was carried out by administration
of heparinized saline. Groups of animals (¢ve/group) were set up for
each test hepoxilin. The hepoxilins were made up in ethanol so that
the test dose (100 Wg/animal) was injected with a Hamilton syringe in
10 Wl ethanol through a plastic Y-injector while 300 Wl saline was
being injected. Hence, the ethanol was carried into the animal while
being diluted with saline. This was important as hepoxilins may pre-
cipitate in saline solution alone. Blood was collected in a plastic sy-
ringe at the designated times and added to Eppendorf tubes. After
1 h, the samples were centrifuged and the serum was collected and
stored at 370‡C until assayed for insulin by RIA. Glucose concen-
trations were measured in the serum samples with a glucosimeter. A
control group was studied in which ethanol alone (in the absence of
hepoxilins) was administered. In another group, glucose was made up
at di¡erent concentrations in water (1, 10, 25 and 50 mg/100 Wl) and
100 Wl of this solution was administered while heparinized saline was
being £ushed into the Y-injector as in the test groups. This was car-
ried out to attempt to titrate the insulin changes by the hepoxilins
relative to the changes observed with glucose administration.
2.3. Measurements
Insulin was measured by a double antibody RIA [13]. Rat insulin
kits were purchased from LINCO (St. Louis, MO, USA) and the
method was modi¢ed to use 20 Wl instead of 100 Wl sample volume.
The detection limit was 18 pmol/l. Glucose was measured by the oxy-
gen consumption method using 10 Wl sample volume [14]. The limit of
detection was 0.3 mmol/l.
3. Results
Administration of a bolus dose of glucose intra-arterially
causes a rapid immediate increase in insulin concentration in
the circulation. Fig. 1 shows time-related changes observed
after the administration of 50 mg glucose (200 mg/kg) in the
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Fig. 1. Temporal changes in insulin and glucose concentrations in blood of inactin-anaesthetized rats in which bolus amounts of glucose
(50 mg/rat = 200 mg/kg) or 10 Wl ethanol (the vehicle for the hepoxilins) were administered through a carotid cannula. Rats had either no access
(‘fasted’) or free access (‘fed’) to food the evening before the experiment. The compounds were injected during the co-injection of 300 Wl of sal-
ine in a plastic Y-injector attached to the carotid cannula. At the times indicated, i.e. 310, 35 min pre-injection and 30 s, 2, 5, 10, 30 and 60
min post-injection of hepoxilin (see arrow at the point of injection), 300 Wl of blood was withdrawn followed by £uid replacement with saline.
Blood samples were allowed to clot and the serum was stored until analysis for insulin and glucose was performed as indicated in the Section 2.
Fig. 2. Temporal changes in insulin concentrations in blood of inactin-anaesthetized ‘fed’ rats in which bolus amounts of the four hepoxilins in-
dicated at a dose of 100 Wg/rat in 10 Wl ethanol were administered intra-arterially as described in Fig. 1. **P6 0.05.
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adult rat. Also shown are the glucose concentrations in blood
of these animals. A signi¢cant di¡erence was observed in the
insulin blood concentration depending on the nutritional state
of the animal, i.e. animals fasted overnight responded with a
lesser release of insulin in the blood than animals that were
allowed free access to food (Fig. 1). The glucose-evoked re-
lease of insulin was dose dependent (not shown).
Initially, we investigated actions of hepoxilins in the fasted
rat but observed no change in insulin blood levels over the
pre-hepoxilin levels (not shown). In view of the experiments
with glucose administration where the fed animals were more
responsive in releasing insulin, we tested the hepoxilins in the
fed animal. Indeed, a rise in blood insulin concentrations was
observed after hepoxilin administration. Fig. 2 compares the
actions of four hepoxilins, i.e. the 8S/8R epimers of HxA3 and
the 10S/10R epimers of HxB3 at the bolus dose of 100 Wg/
animal. Two observations can be noted. First, there is a dif-
ference between the extent of insulin release by each of the
four compounds, the 8S epimer of HxA3 being the most
potent while the 10R epimer of HxB3 seems to have little
e¡ect. Secondly, while the insulin release caused by glucose
administration peaked at the 30 s time point after intra-arte-
rial injection, the hepoxilins peaked at the 2 min sampling
point, suggesting a delay in hepoxilin uptake by the pancreas
or that the hepoxilins act via activation of some other mes-
senger to cause the release of insulin. Neither of the hepoxilins
caused a pronounced change in the glucose concentrations in
blood although the small changes observed were signi¢cant
(Fig. 3).
4. Discussion
Previous studies have shown that HxA3 causes the release
of insulin from isolated incubated islets [15] or perifused islets
of Langerhans [7] in vitro. This was con¢rmed by other in-
vestigators [16]. Hepoxilins also cause the release of calcium
from intracellular stores [17] through a hepoxilin-speci¢c
binding protein [9^11] present in neutrophils and presumably
other cell types which respond to the hepoxilins. Indeed, iso-
lated L-cells respond to hepoxilins with a release of insulin
(C.R. Pace-Asciak, unpublished observations). Hence, the he-
poxilin-evoked release of insulin from the L-cell may be medi-
ated through their actions on calcium.
As hepoxilins are lipidic in nature and rather unstable bio-
logically (through catabolism) and chemically (through epox-
ide ring opening) [18], we wished to know whether hepoxilins
could e¡ect insulin release in vivo, as this could be severely
hindered by limited uptake by the pancreas. The present re-
sults demonstrate that the native hepoxilins, especially those
of the A series, cause a rise in circulating insulin. We found
this release to be a¡ected by the glucose status of the rat,
being insensitive to hepoxilins in the fasted state but signi¢-
cantly active in animals that were allowed free access to food.
Preliminary unpublished observations with tritium-labelled
hepoxilin indicated that approximately 2% of the injected ra-
diolabel was observed in the pancreas at 2 min post-injection,
the peak period of insulin release (Fig. 2), indicating that the
e¡ective potency of the compounds is considerably greater
than the dose used (i.e. at about 2 Wg/rat), assuming that
Fig. 3. Temporal measurements in glucose concentrations in blood of inactin-anaesthetized rats from the experiments shown in Fig. 2.
**P6 0.05.
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most of this radiolabel is accounted for by the native com-
pound and not to inactive catabolites. Hence, hepoxilins pos-
sess considerable biological potency.
These observations o¡er new insights into novel lead com-
pounds involved in the release of insulin in vivo. Because the
native hepoxilins are rather unstable, we are pursuing ways of
stabilizing their structure chemically and biologically with an
aim at developing novel therapeutic agents of potential use in
type II diabetes mellitus.
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